Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + cyclophosphamide + fludarabine (Japan Adult Leukemia Study Group)
- Development stage
- Unknown
- Lead developer
- Cooperative Study Group A for Hematology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This refers to a combination of chemotherapy agents—busulfan, cyclophosphamide, and fludarabine—evaluated in a randomized phase III clinical trial conducted by the Cooperative Study Group A for Hematology (COSAH). The trial compared two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome (MDS): intravenous busulfan plus cyclophosphamide (BuCy) and intravenous busulfan plus fludarabine (BuFlu). Busulfan and cyclophosphamide are alkylating agents that exert cytotoxic effects by cross-linking DNA, thereby inducing cell death. Fludarabine is a purine analog that inhibits DNA synthesis by targeting DNA polymerase and ribonucleotide reductase. The study aimed to compare the efficacy and toxicity profiles of these regimens, finding that while BuCy was associated with higher survival rates, BuFlu demonstrated a more favorable gastrointestinal toxicity profile.
- Other names
- busulfan + cyclophosphamide + busulfan + fludarabine-Cooperative Study Group A for Hematology-leukemia-myelodysplastic syndromeBuCyBuFlubusulfan + cyclophosphamidebusulfan + fludarabine
02
Targets
POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)DNA-directed primase/polymerase protein (PrimPol)DNAGSTA1 (Glutathione S-transferase A1)Pol II (RNA polymerase II elongation factors)LigA (DNA ligase (NAD(+)-dependent))GSTM1 (Glutathione S-transferase Mu 1)GSTP1 (Glutathione S-transferase P)
Beyond the preview
Go deeper on busulfan + cyclophosphamide + fludarabine (Japan Adult Leukemia Study Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + cyclophosphamide + fludarabine (Japan Adult Leukemia Study Group).